Zobrazeno 1 - 10
of 16
pro vyhledávání: '"M. Retuerto-Guerrero"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
C. Valero, M. Garijo Bufort, A. García-Valle, A. López Robles, Cruz Fernández-Espartero, C. Y. Soleto, Javier Loricera, M. Retuerto-Guerrero, José L. Pablos, Elena Aurrecoechea, E. Trujillo
Publikováno v:
Annals of the Rheumatic Diseases. 79:648-649
Background:Different Jakinibs (JAKi) have shown efficacy in rheumatoid arthritis (RA) but in an important proportion of patients, insufficient response leads to therapy withdrawal. The different JAKi show variable selectivity for the four Jak isoform
Autor:
Trinidad Pérez Sandoval, O. Maiz-Alonso, Mireia López-Corbeto, Clara Aguilera Cros, P. Vela-Casasempere, Ivan Castellví, José Antonio Bernal-Vidal, C. Delgado-Beltran, R. Castellanos-Moreira, Miguel A. González-Gay, Sergi Ordoñez, Alejandra López Robles, J. Loricera, Santos Castañeda, Ricardo Blanco, Iván Cabezas-Rodríguez, A. Juan-Mas, Alejandro Olive, B. Alvarez-Rodríguez, Natalia Mena-Vázquez, A. Urruticoechea-Arana, Maria Lopez Lasanta, José Luis Andréu Sánchez, C. Fito-Manteca, S Rodiguéz-Garcia, A. Ruibal-Escribano, Gemma Bonilla, J.M. Blanco, Raquel Almodóvar, Susana Romero-Yuste, Noelia Alvarez-Rivas, Luis Marcelino Arboleya Rodríguez, Samantha Rodríguez-Muguruza, Mireia Moreno, Francisco Ortiz-Sanjuán, C. Hidalgo, Eva Salgado-Pérez, Ivette Casafont-Solé, C. González-Montagut Gómez, I. Villa-Blanco, Manuel Moreno, J. Fernández-Melon, M. Rodíguez-Gómez, R. López-Sánchez, Deseada Palma Sánchez, Rosa Expósito, I. Hernández-Rodriguez, Carmen Carrasco-Cubero, Patricia Carreira, C. Fernández-Díaz, Blanca Garcia-Magallon, E. C. Cervantes Pérez, C. Ojeda-Garcia, M. Retuerto-Guerrero
Publikováno v:
Abstracts Accepted for Publication.
Background Rheumatoid arthritis (RA) may associate with Interstitial Lung Disease (ILD). Disease-modifying anti-rheumatic drug (DMARD) or TNF alfa inhibitors (iTNF), had been involved in the ILD development as well as exacerbation of an existing one.
Autor:
Patricia Lavilla, Álvaro García Martos, Pilar F. Dapica, Pilar Alonso, Sheila Melchor, Diana Vega, M. Retuerto-Guerrero
Publikováno v:
Abstracts Accepted for Publication.
Background: Radioactive synoviorthesis (RS) is the intra-articular injection of a colloidal suspension of particles marked with a radioisotope that selectively irradiates the synovial membrane, respecting bone and cartilage. The radiocolloid is phago
Publikováno v:
Annals of the Rheumatic Diseases. 79:1813.2-1814
Background:Since its first description in 1971 by Schur, many authors have discussed whether rhupus is an overlap syndrome between RA and SLE, a particular form of SLE with prominent and frequently erosive joint involvement,or if it is a distinct cli
Publikováno v:
Annals of the Rheumatic Diseases. 79:1597.2-1598
Background:Rheumatic diseases are associated with accelerated atherosclerosis, and an increase in cardiovascular morbidity and mortality. This process is mediated by classic cardiovascular risk factors (CVRF), chronic inflammation and atherogenic tre
Autor:
N. Costas, Sheila Melchor, M. Retuerto Guerrero, P. Fernández Dapica, José L. Pablos, E. Rodriguez
Publikováno v:
Other orphan diseases.
Background The polymyalgia rheumatica is a rheumatic inflammatory disease more frequent in the eldest population The classic therapy is based on medium doses of corticosteroids followed by a maintenance phase of low doses, generally lasting form 1–
Autor:
M. Retuerto Guerrero, X. Juanola Roura, I. Villa-Blanco, M. Martin Lopez, J. Bachiller-Corral, C.M. Gonzalez Fernandez, R. Ibáñez Bosch, B. García Magallón, Eulalia María Beltrán, J.V. Tovar Beltrán, Javier Manero, María J. Arteaga, Luis Cea-Calvo, Enrique Raya, J.M. Rodríguez-Heredia, J. Pons Dolset, C.A. Egües Dubuc, J.M. Martín Santos, S. García-Carazo, Ana Laiz, Noelia Alvarez-Rivas, Juan José Alegre-Sancho
Publikováno v:
Spondyloarthritis – treatment.
Objectives In this retrospective study we assess the 1 to 3 year probability of persistence on golimumab in patients with spondyloarthritis (SpA), axial SpA or psoriatic arthritis (PsA) who started treatment with golimumab as second biological (after
Autor:
Ana Laiz, B. García Magallón, Yvonne Mestre, S. Fernández, M. Retuerto Guerrero, M. Mosquera, J. Pons Dolset, Luis Cea-Calvo, J. Bachiller-Corral, C.M. Gonzalez Fernandez, Noelia Alvarez-Rivas, I. Villa-Blanco, J.M. Martín Santos, M. Martin Lopez, Enrique Raya, Javier Manero, C.A. Egües Dubuc, J. Rodríguez-Hereida, Juan José Alegre-Sancho, S. García-Carazo, X. Juanola, J.V. Tovar Beltrán, Eulalia María Beltrán, R. Ibáñez Bosch
Publikováno v:
Saturday, 16 JUNE 2018.
Objectives In patients with spondyloarthritis (SpA: axial SpA or psoriatic arthritis [PsA]), treated with golimumab as second biological therapy (after failure or withdrawal of a first anti TNF-α drug), we describe patients’ insights with regard t
Autor:
A Lόpez, C. Άlvarez, Margarita Martin, M. Retuerto Guerrero, Clara Moriano, M Garijo Buffort, C. Iñiguez, T. Pérez Sandoval, AG Valle, E. Diez
Publikováno v:
Poster Presentations.
Background The drugs called Anti-TNF inhibitors are capable of inducing an immune response (immunogenicity) Its effectiveness may be affected by the development of Anti-Drug Antibodies (Ab) Objectives To assess the frequency of appearance of Anti-Dru